Capricor Therapeutics (CAPR) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Capricor Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
March 17, 2016 4:00 PM EDTLOS ANGELES, March 17, 2016 /PRNewswire/ --Â Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the fourth quarter and full year ended December 31, 2015 as well as a business update.
"In 2015 and through the early part of 2016, we expanded the scope of our clinical and preclinical programs as well as strengthened our management team with key hires," said Linda Marbán, Ph.D.,... More
